Intellia Therapeutics Expands Phase III ATTR Cardiomyopathy Trial to 1,200 Patients

Intellia Therapeutics is expanding its Phase III trial for ATTR cardiomyopathy, targeting 1,200 patients as enrollment accelerates. The company's CEO, John M. Leonard, stated that 2025 is a year of excellent execution and exciting clinical updates, with objectives being met or exceeded, supporting a runway through several major milestones.

Intellia Therapeutics (NASDAQ:NTLA) has announced significant progress in its clinical programs, with the company expanding its Phase III trial for ATTR cardiomyopathy to target 1,200 patients. The expansion, which follows strong enrollment in the Phase 3 MAGNITUDE trial, demonstrates the company's ability to meet or exceed internal expectations [1].

In a statement, Intellia's President and Chief Executive Officer, John M. Leonard, M.D., noted that 2025 is a year of excellent execution and exciting clinical updates, with objectives being met or exceeded. The company has reported strong enrollment numbers that have allowed it to plan to enhance the Phase 3 MAGNITUDE trial in ATTR-CM and accelerate the completion of the Phase 3 HAELO study in HAE ahead of original plans [1].

The expansion of the MAGNITUDE trial to 1,200 patients is expected to strengthen the potential statistical power, particularly in the stabilizer stratum, which will be critical for regulatory approval and payer acceptance without delaying timelines. The HAE program for lonvoguran ziclumeran (lonvo-z) is also showing remarkable progress, with randomization in the Phase 3 HAELO study now expected to complete in Q3 2025, ahead of schedule [1].

Intellia's Q2 2025 financial performance shows disciplined resource allocation amid accelerating clinical progress. The company reported a net loss of $101.3 million, significantly improved from the $147.0 million loss in Q2 2024. This 31% reduction in net loss demonstrates the company's ability to advance multiple late-stage programs while controlling expenses [1].

The company ended Q2 with $630.5 million in cash, providing runway into the first half of 2027 and through their anticipated first commercial launch. The $17.2M decrease in R&D expenses year-over-year reflects improved operational efficiency following their portfolio prioritization, while the commercial infrastructure buildout continues in preparation for launch [1].

Strong clinical progress and efficient cash management position Intellia well for upcoming commercial phase despite Q2 net loss. The company's expansion of the MAGNITUDE trial and the accelerated timeline for the HAELO study could potentially bring forward revenue opportunities. The commercial team buildout, including key leadership hires in sales, operations, and market access, indicates the company is methodically preparing for product launches while maintaining fiscal discipline [1].

References:
[1] https://www.stocktitan.net/news/NTLA/intellia-therapeutics-announces-second-quarter-2025-financial-zqecci6852pr.html